Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: BioCryst is a biotechnology company utilizing structure-based drug design to develop small molecule pharmaceuticals. Its principal product candidates include Peramivir (influenza), BCX4208 (gout), and Forodesine (cutaneous T-cell lymphoma and chronic lymphocytic leukemia). The company relies heavily on collaborative agreements and government contracts for funding and commercialization.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenues | $62.4 million | $74.6 million |
| Research & Development Expenses | $82.5 million | $72.3 million |
| General & Administrative Expenses | $14.2 million | $11.5 million |
| Net Loss | $(33.9) million | $(13.5) million |
| Net Loss Per Share (Basic & Diluted) | $(0.76) | $(0.35) |
| Cash, Cash Equivalents & Securities | $66.3 million | $94.3 million |
| Total Assets | $109.4 million | $142.2 million |
| Long-term Deferred Revenue | $15.9 million | $18.4 million |
Liquidity: The company reported a net cash burn of $27.9 million in 2010. As of December 31, 2010, cash and marketable securities totaled $66.3 million. Management estimated resources would fund operations for at least 24 months following the filing date, contingent on future funding from the U.S. Department of Health and Human Services (HHS) and a subsequent financing transaction.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 16% to $62.4 million from $74.6 million in 2009. This was primarily due to the absence of a $22.5 million one-time sale of Peramivir to HHS under an Emergency Use Authorization (EUA) in 2009. Additionally, $0.7 million in royalty revenue from Shionogi recorded in Q1 2010 was reversed in Q4 2010 due to product returns.
- Increased Loss: Net loss widened significantly to $33.9 million from $13.5 million, driven by higher R&D expenses ($10.2 million increase) and lower revenues.
- R&D Spend: R&D expenses increased to $82.5 million, reflecting higher development costs for Peramivir and BCX4208, partially offset by reduced costs for Forodesine.
- Inventory: Inventory levels dropped from $6.3 million in 2009 to $0.9 million in 2010. In 2009, the company fully reserved $4.0 million of capitalized Peramivir inventory due to uncertainty regarding future demand.
Guidance, Outlook, and Risks
Recent Developments and Outlook
- HHS Contract: On February 24, 2011, HHS awarded a $55.0 million contract modification to fund the completion of Phase 3 development of i.v. Peramivir for hospitalized patients, extending the total award to $234.8 million through December 2013.
- Royalty Monetization: On March 9, 2011, the company completed a $30.0 million financing transaction by issuing "PhaRMA Notes" secured by future royalty and milestone payments from its partner Shionogi. Net proceeds were approximately $23.0 million.
- Clinical Progress:
- Peramivir: Phase 3 safety/virology study (303) showed the drug was safe and well-tolerated. The ongoing Phase 3 efficacy study (301) was modified to increase enrollment to 600 subjects.
- BCX4208: Phase 2 studies for gout showed statistically significant reduction in serum uric acid. A Phase 2b study as add-on therapy was initiated in December 2010.
- Forodesine: Pivotal CTCL study results were mixed (11% response rate). The company decided not to pursue further U.S. development without a partner, leading to a dispute with partner Mundipharma.
Risks and Contingencies
- Profitability: The company has incurred losses since inception and expects to continue doing so. It has no marketed products in the U.S. and relies on external funding.
- Government Contract Risk: A significant portion of revenue depends on HHS reimbursement. The contract is terminable by the government for convenience or default, and costs are subject to audit.
- Partner Disputes: Mundipharma has initiated dispute resolution proceedings regarding the future of Forodesine development and potential cost obligations.
- Financing Obligations: The PhaRMA Notes carry a 14% interest rate. If Shionogi royalties are insufficient to service this debt, investors may foreclose on the collateral, potentially limiting BioCryst's access to future royalties.
- Currency Risk: The company entered a foreign currency hedge arrangement related to the PhaRMA Notes, which may cause quarterly earnings volatility.
Investor Verification Checklist
- HHS Funding Stability: Verify the terms and security of the $55 million HHS contract modification and the company's ability to meet performance milestones to avoid termination.
- PhaRMA Note Servicing: Assess the sufficiency of projected Shionogi royalties to cover the 14% interest and principal payments on the $30 million debt obligation.
- Forodesine Dispute: Monitor the outcome of the dispute resolution with Mundipharma to determine potential financial liabilities or loss of rights.
- Cash Runway: Confirm the company's cash burn rate against the $66.3 million cash balance and expected HHS reimbursements to ensure solvency through 2012.
- Peramivir Clinical Data: Review detailed results from the modified Phase 3 efficacy study (301) to gauge the likelihood of FDA approval and commercial viability.